PLAY PODCASTS
Rethinking HER2-Targeted Therapy After DESTINY-04

Rethinking HER2-Targeted Therapy After DESTINY-04

Oncology News Central Peer-Spectives

July 7, 202211m 15s

Audio is streamed directly from the publisher (mcdn.podbean.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

William Gradishar, MD, talks with Robert Figlin, MD, about breast cancer research highlights from the 2022 American Society of Clinical Oncology Annual Meeting, including results from DESTINY-Breast04 and new data on CDK4/6 inhibitors from the PALOMA-2 and MAINTAIN trials.